Lipocine Inc.

LPCN

US53630X2036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 04/06/2024 am IST			5-day change	1st Jan Change
6.9 ^USD	-0.29%		+0.15%	+147.31%

09/05	Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M	MT
09/05	Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Lipocine Inc. Terminates the Employment of Jyrki Mattila as Executive Vice President and Chief Business Officer

July 08, 2017 at 02:30 am IST

On July 7, 2017, Lipocine Inc. terminated the employment of Jyrki Mattila as executive vice president and chief business officer of the company.

Latest news about Lipocine Inc.

Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M	09/05	MT
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	01/05	CI
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	12/04	MT
Top Premarket Gainers	11/04	MT
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	11/04	CI
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	28/03	CI
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug	25/03	MT
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	25/03	CI
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	06/02	CI
Lipocine Enters Licensing Deal With Verity Pharmaceuticals for TLANDO in US, Canada	19/01	MT
Lipocine and Verity Pharma Enter into License Agreement for Tlando® Franchise in the U.S. and Canada	18/01	CI
Lipocine Files up to $150 Million Mixed Shelf	23/11	MT
Lipocine Inc. Announces Results of its Phase 2 Study Evaluating LPCN 1148	14/11	CI
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Lipocine Inc. Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression	26/23/26	CI
Lipocine Inc. Enters into License Agreement with Antares Pharma, Inc	07/23/07	CI
Lipocine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
North American Morning Briefing : Investors Await -2-	07/23/07	DJ
Lipocine Inc. Announces Positive Topline Results from A Phase 2 Clinical Study of LPCN 1148	27/23/27	CI
Lipocine Inc.(NasdaqCM:LPCN) dropped from Russell 3000E Growth Index	23/23/23	CI
Lipocine Inc.(NasdaqCM:LPCN) dropped from Russell Microcap Growth Index	23/23/23	CI
Lipocine Inc.(NasdaqCM:LPCN) dropped from Russell 3000E Index	23/23/23	CI
Lipocine Inc.(NasdaqCM:LPCN) dropped from Russell Microcap Index	23/23/23	CI

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.9 USD

Average target price

33.19 USD

Spread / Average Target

+381.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIPOCINE INC.	+147.31%	36.9M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	121B
REGENERON PHARMACEUTICALS, INC.	+12.66%	107B
BIONTECH SE	-2.53%	24.82B
ARGENX SE	+1.14%	22.48B
GENMAB A/S	-9.35%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-18.92%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	14.08B
SAREPTA THERAPEUTICS, INC.	+28.83%	11.74B

Bio Therapeutic Drugs

Lipocine Inc.

Equities

LPCN

US53630X2036

Biotechnology & Medical Research

Lipocine Inc. Terminates the Employment of Jyrki Mattila as Executive Vice President and Chief Business Officer

Latest news about Lipocine Inc.

Chart Lipocine Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs